This is a preview of subscription content, log in via an institution to check access.
References
Baum JP, Niesen A, Hertel A, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994; 73(3 Suppl.): 1121–5
Schultes BC, Gordon A, Ehlen T, et al. Induction of tumor- and CA125-specific T cell responses in patients (pts) with epithelial ovarian cancer (EOC) treated with OvaRex® MAb-B43.13 [abstract 717], Cancer Res 2002 Mar; 43: 144
Ehlen TG, Gordon AN, Fingert HJ, et al. Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC) [abstract 31]. Proc Am Soc Clin Oncol 2002 May 18; 21: 9a (part 1)
Schultes BC, Nicodemus CF, Berek JS, et al. Use of OvaRex® MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as a single agent post first-line therapy and in combination with chemotherapy in recurrent disease [abstract; online]. Available from URL: http://www.eortc.be/ [Accessed 2002 Nov 26]
Zhang L, Conejo-Garcia JR, Katsoros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203–13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baum, R.P. Oregovomab. Am J Cancer 2, 135–136 (2003). https://doi.org/10.2165/00024669-200302020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200302020-00007